摘要
目的观察抗程序性细胞死亡蛋白-1(PD-1)单抗治疗中晚期结直肠癌的临床效果及其对肠道菌群的影响。方法将2022年3月至2023年3月暨南大学附属第六医院就诊的中晚期结直肠癌患者50例纳入研究,根据随机数字表法分为2组。对照组23例给予常规治疗,观察组27例在对照组基础上给予抗PD-1单抗治疗。比较2组治疗前后免疫功能、肿瘤标志物水平、肠道屏障功能、肠道菌群的变化,并统计2组近期病情控制率。结果治疗后2组各项免疫功能指标、肿瘤标志物水平、肠道屏障功能指标、肠道菌群含量均较治疗前改善(P<0.05);治疗后观察组CD8^(+)、大肠杆菌数量、二胺氧化酶、D-乳酸和细菌内毒素水平均低于对照组(P<0.05),CD4^(+)、CD4^(+)/CD8^(+)、双歧杆菌、乳酸杆菌数量水平均高于对照组(P<0.05)。观察组近期病情控制率为88.89%,明显高于对照组的65.22%(P<0.05)。结论抗PD-1单抗治疗中晚期结直肠癌疗效较好,可通过增强机体免疫功能,纠正肠道菌群紊乱,修复肠道屏障功能。
Objective To investigate the effect of anti-programmed death protein-1(PD-1)antibody in the treatment of patients with advanced colorectal cancer,and its impact on gut microbiota.Method A total of 50 patients with advanced colorectal cancer admitted to the Sixth Affiliated Hospital of Jinan University were included in the study.The enrollment period was concentrated from March 2022 to March 2023.According to the random number table method,they were divided into the control group and the observation group.The control group,with 23 patients included,received routine treatment,and the observation group,with 27 patients included,received anti PD-1 antibody on the basis of the control group.The changes of immune function,tumor marker levels,intestinal microbiota,and intestinal barrier function between the two groups before and after treatment,and to compare the short-term disease control rates between the two groups.Results The immune function indicators,intestinal microbiota content,and intestinal barrier function indicators of the two groups after treatment were all better than those before treatment,and the difference was statistically significant(P<0.05);The CD4^(+),CD8^(+),CD4^(+)/CD8^(+),Escherichia coli,Bifidobacterium,Lactobacillus,Diamine Oxidase,Bacterial Endotoxins,and D-lactate values of the patients in the observation group were better than those in the control group,and the difference was statistically significant(P<0.05).The levels of glycoprotein antigen 125,carbohydrate antigen 199,and carcinoembryonic antigen in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).The short-term disease control rate in the observation group was higher than that in the control group(88.89%vs 65.22%),and the difference was statistically significant(P<0.05).Conclusion Anti-PD-1 antibody Cindilimab injection has a significant clinical effect in the treatment of advanced colorectal cancer,Enhancing the immune system,correcting gut microbiota imbalance,and repairing intestinal barrier function.
作者
皮红泉
刘卉芳
祝函函
杨梦
PI Hongquan;LIU Huifang;ZHU Hanhan;YANG Meng(Department of Clinical Laboratory,The Sixth Affiliated Hospital of Jinan University,Guangdong Province,Dongguan 523573,China)
出处
《转化医学杂志》
2024年第9期1489-1493,共5页
Translational Medicine Journal
基金
广州市科技计划项目资助(编号:202201020571)。
